In preclinical studies and clinical trials, the inhibition of the CXCR4 receptor by, for example, the CXCR4 antagonists AMD3100 and TN14003 and the CXCL12 analogue CTCE-9908, showed promising antitumor effects in different cancers, including pancreatic cancer [40, 85]. This evidence concerns the gene CXCR4 and cancer.